Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials
ABSTRACT Introduction Myelofibrosis is characterized by debilitating constitutional symptoms and anemia, which negatively impact survival and quality of life. Red blood cell transfusions form the basis of anemia management in myelofibrosis but dependence on transfusions is further associated with po...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.70075 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850158173169647616 |
|---|---|
| author | Ruben A. Mesa Moshe Talpaz Flora Mazerolle Boris Gorsh Manal M'Hari Antoine Regnault Catherine Ellis Zhaohui Wang Molly Purser Tom Liu Bryan Strouse Dwaipayan Patnaik |
| author_facet | Ruben A. Mesa Moshe Talpaz Flora Mazerolle Boris Gorsh Manal M'Hari Antoine Regnault Catherine Ellis Zhaohui Wang Molly Purser Tom Liu Bryan Strouse Dwaipayan Patnaik |
| author_sort | Ruben A. Mesa |
| collection | DOAJ |
| description | ABSTRACT Introduction Myelofibrosis is characterized by debilitating constitutional symptoms and anemia, which negatively impact survival and quality of life. Red blood cell transfusions form the basis of anemia management in myelofibrosis but dependence on transfusions is further associated with poorer survival and quality of life. Methods Time without transfusion reliance (TWiTR), a method integrating transfusion dependence and survival quality, was applied to three Phase 3 trials of momelotinib in myelofibrosis. Results TWiTR demonstrated that patients treated with momelotinib versus comparators spent more time free from transfusions and anemia events. Conclusion Momelotinib may lead to improved survival quality for patients with myelofibrosis. Trial registration ClinicalTrials.gov identifiers: NCT01969838, NCT02101268, and NCT04173494 |
| format | Article |
| id | doaj-art-ed9ae1efb1354cd1a496c86bae57f8e2 |
| institution | OA Journals |
| issn | 2688-6146 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj-art-ed9ae1efb1354cd1a496c86bae57f8e22025-08-20T02:23:57ZengWileyeJHaem2688-61462025-06-0163n/an/a10.1002/jha2.70075Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM TrialsRuben A. Mesa0Moshe Talpaz1Flora Mazerolle2Boris Gorsh3Manal M'Hari4Antoine Regnault5Catherine Ellis6Zhaohui Wang7Molly Purser8Tom Liu9Bryan Strouse10Dwaipayan Patnaik11Atrium Health Wake Forest Baptist Comprehensive Cancer Center Winston‐Salem North Carolina USAUniversity of Michigan Comprehensive Cancer Center Ann Arbor Michigan USAModus Outcomes a company of THREAD Lyon FranceGSK plc Collegeville Pennsylvania USAModus Outcomes a company of THREAD Lyon FranceModus Outcomes a company of THREAD Lyon FranceGSK plc Collegeville Pennsylvania USAGSK plc Collegeville Pennsylvania USAGSK plc Collegeville Pennsylvania USAGSK plc Collegeville Pennsylvania USAGSK plc Collegeville Pennsylvania USAGSK plc Collegeville Pennsylvania USAABSTRACT Introduction Myelofibrosis is characterized by debilitating constitutional symptoms and anemia, which negatively impact survival and quality of life. Red blood cell transfusions form the basis of anemia management in myelofibrosis but dependence on transfusions is further associated with poorer survival and quality of life. Methods Time without transfusion reliance (TWiTR), a method integrating transfusion dependence and survival quality, was applied to three Phase 3 trials of momelotinib in myelofibrosis. Results TWiTR demonstrated that patients treated with momelotinib versus comparators spent more time free from transfusions and anemia events. Conclusion Momelotinib may lead to improved survival quality for patients with myelofibrosis. Trial registration ClinicalTrials.gov identifiers: NCT01969838, NCT02101268, and NCT04173494https://doi.org/10.1002/jha2.70075JAK inhibitormomelotinibmyelofibrosisquality of lifesurvivaltransfusions |
| spellingShingle | Ruben A. Mesa Moshe Talpaz Flora Mazerolle Boris Gorsh Manal M'Hari Antoine Regnault Catherine Ellis Zhaohui Wang Molly Purser Tom Liu Bryan Strouse Dwaipayan Patnaik Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials eJHaem JAK inhibitor momelotinib myelofibrosis quality of life survival transfusions |
| title | Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials |
| title_full | Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials |
| title_fullStr | Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials |
| title_full_unstemmed | Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials |
| title_short | Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials |
| title_sort | time without transfusion reliance twitr integrating survival quality into myelofibrosis treatment strategies based on the phase 3 simplify 1 simplify 2 and momentum trials |
| topic | JAK inhibitor momelotinib myelofibrosis quality of life survival transfusions |
| url | https://doi.org/10.1002/jha2.70075 |
| work_keys_str_mv | AT rubenamesa timewithouttransfusionreliancetwitrintegratingsurvivalqualityintomyelofibrosistreatmentstrategiesbasedonthephase3simplify1simplify2andmomentumtrials AT moshetalpaz timewithouttransfusionreliancetwitrintegratingsurvivalqualityintomyelofibrosistreatmentstrategiesbasedonthephase3simplify1simplify2andmomentumtrials AT floramazerolle timewithouttransfusionreliancetwitrintegratingsurvivalqualityintomyelofibrosistreatmentstrategiesbasedonthephase3simplify1simplify2andmomentumtrials AT borisgorsh timewithouttransfusionreliancetwitrintegratingsurvivalqualityintomyelofibrosistreatmentstrategiesbasedonthephase3simplify1simplify2andmomentumtrials AT manalmhari timewithouttransfusionreliancetwitrintegratingsurvivalqualityintomyelofibrosistreatmentstrategiesbasedonthephase3simplify1simplify2andmomentumtrials AT antoineregnault timewithouttransfusionreliancetwitrintegratingsurvivalqualityintomyelofibrosistreatmentstrategiesbasedonthephase3simplify1simplify2andmomentumtrials AT catherineellis timewithouttransfusionreliancetwitrintegratingsurvivalqualityintomyelofibrosistreatmentstrategiesbasedonthephase3simplify1simplify2andmomentumtrials AT zhaohuiwang timewithouttransfusionreliancetwitrintegratingsurvivalqualityintomyelofibrosistreatmentstrategiesbasedonthephase3simplify1simplify2andmomentumtrials AT mollypurser timewithouttransfusionreliancetwitrintegratingsurvivalqualityintomyelofibrosistreatmentstrategiesbasedonthephase3simplify1simplify2andmomentumtrials AT tomliu timewithouttransfusionreliancetwitrintegratingsurvivalqualityintomyelofibrosistreatmentstrategiesbasedonthephase3simplify1simplify2andmomentumtrials AT bryanstrouse timewithouttransfusionreliancetwitrintegratingsurvivalqualityintomyelofibrosistreatmentstrategiesbasedonthephase3simplify1simplify2andmomentumtrials AT dwaipayanpatnaik timewithouttransfusionreliancetwitrintegratingsurvivalqualityintomyelofibrosistreatmentstrategiesbasedonthephase3simplify1simplify2andmomentumtrials |